Daratumumab in combination with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable: Appraisal consultation document

DRAFT guidance does not recommend use, within its marketing authorisation, as induction and consolidation treatment as cost-effectiveness estimates are likely to be higher than that considered acceptable by NICE.

National Institute for Health and Care Excellence